What is Alkahest (Alka)?
Alkahest is a biopharmaceutical company specializing in plasma therapies. It targets neurodegenerative and age-related diseases with transformative therapies derived from blood. The company focuses on Alzheimer’s and Parkinson’s diseases, age-related macular degeneration (AMD), etc.
Who is the CEO of Alkahest?
Alkahest's key executives are Karoly Nikolich, Steven Braithwaite and Tammy Kent. How many employees does Alkahest have? Alkahest has 88 employees.
What is the upside for Alkami technology (ALK) stock?
Their forecasts range from $33.00 to $50.00. On average, they anticipate Alkami Technology's stock price to reach $41.43 in the next twelve months. This suggests a possible upside of 100.4% from the stock's current price. View analysts' price targets for Alkami Technology or view top-rated stocks among Wall Street analysts.
Where can I buy alkt stock?
Shares of ALKT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Alkahest Comparisons
ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris
Alkahest Signals
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Harnessing Chronokines
Aging is the dominant risk factor in degenerative diseases, particularly those with no or few therapeutic solutions. Alkahest is decoding the plasma proteome to create groundbreaking therapies that halt or reverse these harmful effects of aging in critical diseases.
Chronokines as Therapeutic Targets
We are developing clinical candidates that increase or decrease the levels of key circulating chronokines to either promote innate and natural restorative biological processes or inhibit pathological degenerative processes.
Who is the CEO of Alkahest?
Karoly Nikolich, CEO of Alkahest, said, “We are excited to join forces with Grifols, an industry leader in plasma-derived medicines, to realize our shared vision and mission of delivering innovative medicines for age-related diseases on an ambitious scale.”
What is Alkahest focused on?
In addition to the clinical development of specific plasma fractions and protein inhibitors, Alkahest is focused on developing a complete understanding of the human plasma proteome. This unique proteomic platform of targets will help Grifols and Alkahest to unlock new therapeutics and diagnostics, develop new plasma proteins, new indications for currently licensed plasma proteins, biomarkers for diagnostics, recombinant proteins and antibodies as well as small-molecule drugs.
What is the Alkahest map?
Alkahest has developed a map of the human plasma proteome facilitating the identification of plasma proteins and their recombinant analogues as potential therapeutic medicines
Why did Grifols acquire Alkahest?
Grifols to acquire Alkahest to enhance discovery research and development to identify innovative therapies for age-related diseases based upon an understanding of the human plasma proteome. « Back to News. Grifols to acquire remaining stock of Alkahest, Inc. in exchange for a total price of $146 million, on a debt-free basis, ...
Is Alkahest a wholly owned subsidiary?
Understanding the plasma proteome is the key to Alkahest’s comprehensive discovery and development platform delivering transformational therapeutics. Alkah est, as a wholly owned subsidiary within the Grifols innovation office (GIANT), will focus on proteins with biological impact that change with age. Thus far, more than 8,000 separate proteins have been identified by Alkahest and using advanced techniques of molecular analysis at the cellular level, an array of new products are expected to enter Grifols’ discovery and development pipeline and bring new therapeutic medicines to market.
Overview Suggest Edit
Alkahest is a biopharmaceutical company specializing in plasma therapies. It targets neurodegenerative and age-related diseases with transformative therapies derived from blood. The company focuses on Alzheimer’s and Parkinson’s diseases, age-related macular degeneration (AMD), etc.
917 Twitter followers
Alkahest has 917 Twitter Followers. The number of followers has decreased 0.1% month over month and increased 0.3% quarter over quarter
Alkahest Strengthens Management Team with Addition of César Cerezo as Chief Medical Officer
SAN CARLOS, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Alkahest, Inc., a clinical-stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases and a subsidiary of Grifols, today announced the appointment of Dr. César Cerezo M.D., Ph.D., as…
Grifols to acquire Alkahest to enhance discovery research and development to identify innovative therapies for age-related diseases based upon an understanding of the human plasma proteome
BARCELONA, Spain, and SAN CARLOS, Calif., Sept. 7, 2020 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, today announced it has entered into a transaction...
About
Alkahest develops therapies derived from blood to treat neurological diseases, with an emphasis on age-related cognitive decline.
Highlights
View contacts for Alkahest to access new leads and connect with decision-makers.
Details
Alkahest develops therapies derived from blood to treat neurological diseases, with an emphasis on age-related cognitive decline. It collaborates with Barcelona, Spain-based Grifols, a global healthcare company producer of plasma therapies.
What is Alkami Technology's stock symbol?
Alkami Technology trades on the NASDAQ under the ticker symbol "ALKT."
When is Alkami's second quarter 2021 earnings?
Alkami Technology issued an update on its second quarter 2021 earnings guidance on Tuesday, June, 8th. The company provided earnings per share guidance of $- for the period. The company issued revenue guidance of $34 million-35 million.
What is MarketBeat ratings?
MarketBeat's community ratings are surveys of what our community members think about Alkami Technology and other stocks. Vote “Outperform” if you believe ALKT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ALKT will underperform the S&P 500 over the long term. You may vote once every thirty days.
What is Alkami technology?
Alkami Technology, Inc. offers a cloud-based digital banking platform to serve banks and credit unions in the United States. The company's platform allows financial institutions to onboard and engage new users, accelerate revenues, and enhance operational efficiency, with the support of a proprietary, cloud-based, multi-tenant architecture. It offers an end- to- end set of software products, which include Alkami Platform, Retail Banking Solutions, Business Banking Solutions, and The Alkami Difference. The company was founded in 2009 and is headquartered in Plano, Texas.
When did Alkami Technology's lock up period expire?
Alkami Technology's lock-up period expired on Monday, October 11th. Alkami Technology had issued 6,000,000 shares in its IPO on April 14th. The total size of the offering was $180,000,000 based on an initial share price of $30.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the expiration of the lock-up period.
Is Alkami Technology a buy?
Alkami Technology has received a consensus rating of Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.
Does Alkami pay dividends?
Alkami Technology does not currently pay a dividend.
